Compare · HSDT vs MDT
HSDT vs MDT
Side-by-side comparison of Solana Company (HSDT) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSDT and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $104.85B, about 1414.1x HSDT ($74.2M).
- Over the past year, HSDT is down 96.7% and MDT is down 7.8% - MDT leads by 88.9 points.
- MDT has been more active in the news (16 items in the past 4 weeks vs 14 for HSDT).
- MDT has more recent analyst coverage (25 ratings vs 3 for HSDT).
- Company
- Solana Company
- Medtronic plc.
- Price
- $1.38+9.52%
- $80.66-1.20%
- Market cap
- $74.2M
- $104.85B
- 1M return
- -36.11%
- +3.49%
- 1Y return
- -96.71%
- -7.80%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 14
- 16
- Recent ratings
- 3
- 25
Solana Company
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest HSDT
- Director Jiang Cosmo Yi exercised 1,005,040 shares at a strike of $0.00 and covered exercise/tax liability with 610 shares (SEC Form 4)
- SEC Form 4 filed by Director Jiang Cosmo Yi
- Solana Company filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 424B5 filed by Solana Company
- SEC Form SD filed by Solana Company
- Director Straw Edward M was granted 6,360 shares, increasing direct ownership by 291% to 8,542 units (SEC Form 4)
- Director Mello Sergio was granted 6,360 shares (SEC Form 4)
- Director Lee Michel Kai Tai was granted 6,360 shares (SEC Form 4)
- Director Walter Blane was granted 6,360 shares, increasing direct ownership by 291% to 8,542 units (SEC Form 4)
- Amendment: Director Straw Edward M was granted 2,180 shares, increasing direct ownership by 109,000% to 2,182 units (SEC Form 4)
Latest MDT
- Medtronic upgraded by BTIG Research with a new price target
- Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
- Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
- morph Launches the World's First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications
- SVP, Chief HR Officer Walter Matthew R. converted options into 9,149 units of Ordinary Shares, increasing direct ownership by 28% to 41,529 units (SEC Form 4)
- EVP & Pres Neuroscience Wall Brett A. converted options into 26,907 units of Ordinary Shares, increasing direct ownership by 49% to 82,183 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey converted options into 94,963 units of Ordinary Shares, increasing direct ownership by 38% to 343,099 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael converted options into 18,994 units of Ordinary Shares, increasing direct ownership by 37% to 70,593 units (SEC Form 4)